Literature DB >> 2164069

Tumor idiotype vaccines. VII. Analysis and correlation of structural, idiotypic, and biologic properties of protective and nonprotective Ab2.

S Raychaudhuri1, C Y Kang, S V Kaveri, T Kieber-Emmons, H Köhler.   

Abstract

We have previously generated and used anti-Id mAb (Ab2) to induce protective immunity against the L1210 DBA/2 tumor and for immunotherapy of established tumors. Among various anti-Id that were typed serologically as internal image Ab2 of the mouse mammary tumor virus tumor-associated Ag gp52, only one induced protective immunity and was effective in immunotherapy. In this study we compared the structural, idiotypic, and network properties of the protective and nonprotective antiidiotypic antibodies. The DNA sequence of the variable regions of six anti-Id was determined. The VH sequence of four Ab2, including the protective Ab2, are highly homologous, whereas the VL sequences differ and were assigned to different Vk families. In addition, the DH sequence region of the same four Ab2 are identical, whereas one is highly homologous and another one without homology. Search for amino acid sequence homologies between the Ab2 and gp52 showed the strongest similarities in the CDR2 of the L chain from the protective Ab2. In addition, the CDR2 region also had homology with a T cell epitope on gp52. The biologic basis of effective idiotypic mimicry was studied at the level of Ab3 induced by the Ab2. Id inhibition analysis using Ab3 induced by either protective or nonprotective Ab2, revealed differences. Thus, there is evidence for differences among the Ab1-Ab2-Ab3 cascade induced by protective and nonprotective anti-Id.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2164069

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Idiotype network components are involved in the murine immune response to simian virus 40 large tumor antigen.

Authors:  R L Mernaugh; M H Shearer; R K Bright; R E Lanford; R C Kennedy
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  A Cayley tree immune network model with antibody dynamics.

Authors:  R W Anderson; A U Neumann; A S Perelson
Journal:  Bull Math Biol       Date:  1993-11       Impact factor: 1.758

Review 3.  Idiotypic antibody immunotherapy of cancer.

Authors:  M B Chatterjee; K A Foon; H Köhler
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

Review 4.  Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.

Authors:  Rachel N Grisham; Jonathan Berek; Jacobus Pfisterer; Paul Sabbatini
Journal:  Immunotherapy       Date:  2011-02       Impact factor: 4.196

5.  Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?

Authors:  J Fagerberg; J E Frödin; H Wigzell; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

6.  Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy?

Authors:  J Fagerberg; J E Frödin; P Ragnhammar; M Steinitz; H Wigzell; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

7.  Human anti-phosphorylcholine antibodies share idiotopes and are self-binding.

Authors:  R Halpern; S V Kaveri; H Köhler
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

8.  Tumor idiotype vaccines. VIII. Analysis of protective idiotype in sera and hybridomas derived from tumor-bearing mice with long-term survival.

Authors:  J J Chen; H Kohler
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

Review 9.  Biological therapy: approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic target.

Authors:  A P Zbar; N R Lemoine; M Wadhwa; H Thomas; D Snary; W A Kmiot
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

10.  The promise of the anti-idiotype concept.

Authors:  Thomas Kieber-Emmons; Bejatohlah Monzavi-Karbassi; Anastas Pashov; Somdutta Saha; Ramachandran Murali; Heinz Kohler
Journal:  Front Oncol       Date:  2012-12-19       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.